Peptide Based Therapeutics Summit
When:
Tuesday, Apr 23, 2024 9:30a -
Thursday, Apr 25, 2024 3:30p
Tuesday, Apr 23, 2024 9:30a -
Thursday, Apr 25, 2024 3:30p
Where:
Hilton Boston Logan Airport
One Hotel Drive
Boston, Massachusetts 02128
Admission:
$2599.00 - $5097.00
Hosted by:
Categories:
Lectures & Conferences
Event website:
https://go.evvnt.com/2184892-0?pid=5248
Positioned in the goldilocks spot between small molecules and biologics, peptide therapeutics have undergone an exciting uphill trajectory within the last decade. Fuelled by advances in synthesis and screening technologies, together with novel design and delivery strategies to surmount their inherent drawbacks, this modality is showing new levels of promise. The momentum behind this exciting modality is evidenced in the billion-dollar deals from industry giants such as Genentech and Merck, signalling a surge in interest from an expanding array of companies venturing into the field of next-generation peptide-based drugs.
The first industry-focused event dedicated towards this exciting new modality, the Peptide Based Therapeutics Summit will unite pioneers from Johnson and Johnson, Fog Pharma, Genentech and PeptiDream, spanning diverse diseases and therapeutic approaches. Whether you're focused on peptide-drug conjugates, bicyclic or macro-cyclic peptides, PCSK9, GLP, or any other peptide based therapeutic, this is an invaluable opportunity to learn from peers, accelerate discovery and de-risk the development of your peptide therapeutics.
As we enter the third wave of peptide-based therapeutics, this therapeutic and disease agnostic meeting will bring together the leading minds in early discovery, pre-formulation, heads of peptide drug development and pioneering peptide chemists. Together, we will dissect challenges related to improving peptide stability, raising oral bioavailability and balancing cell permeability with intracellular target selectivity, as well as exploring how the latest cutting-edge technology can help you arrive at the optimal lead compound. Join this meeting to help shape the trajectory of these remarkable drugs across various therapeutic landscapes.
URLs:
Tickets: https://go.evvnt.com/2184892-2?pid=5248
Brochure: https://go.evvnt.com/2184892-3?pid=5248
Prices:
Conference + 2 Workshops - Drug Developer Pricing : USD 4197.00,
Conference + 1 Workshop - Drug Developer Pricing: USD 3598.00,
Conference Only - Drug Developer Pricing: USD 2999.00,
Conference + 2 Workshops - Solution Provider Pricing: USD 5097.00,
Conference + 1 Workshop - Solution Provider Pricing: USD 4398.00,
Conference Only - Solution Provider Pricing: USD 3699.00,
Conference + 2 Workshops - Academic Pricing: USD 3597.00,
Conference + 1 Workshop - Academic Pricing: USD 3098.00,
Conference Only - Academic Pricing: USD 2599.00
Speakers: Andy Slee, Chief Scientific Officer, Protagenic Therapeutics, Cameron Pye, Chief Executive Officer, Unnatural Products, David Brayden, Professor - Advanced Drug Delivery, University College Dublin, Hiroaki Suga, Co-Founder and Professor, PeptiDream and University of Tokyo, Jakob Fuhrmann, Senior Principal Scientist, Genentech, Joe Cannon, Scientific Associate Director, Biotransformation, Bristol Myers Squibb, Jonathan Hurov, Head of Discovery Biology, Fog Pharma, Joshua Kritzer, Professor, Department of Chemistry, Tufts University, Joshua Schwochert, Chief Scientific Officer, Unnatural Products, Kristian Stromgaard, Professor, Center for Biopharmaceuticals, University of Copenhagen, Lauren Goodrich, Vice President, Therapeutic Discovery, Nimble Therapeutics, Mengshi Li, Director of Discovery, Perspective Therapeutics, Michael Needle, Chief Medical Officer, Cybrexa, Pete Gough, Chief scientific officer, Nimble Therapeutics, Ping Ye, Senior Scientist, UCB, Sandeep Somani, Principal Scientist, Johnson and Johnson, Scott Plevy, Executive Vice President, Head of Discovery and Therapeutic Lead, Gastroenterology, Protagonist Therapeutics, Thomas von Erlach, Chief Scientific Officer, Vivtex, Tomi Sawyer, Chief Drug Hunter and President, Maestro Therapeutics
